| Long term nebulised gentamicin in patients with bronchiectasis |
Gentamicin |
80 mg |
Phase IV randomized placebo controlled study based on targeted nebulised gentamicin to the airways with the aim of reducing bacterial burden and limiting neutrophil airways inflammation |
University of Edinburgh/2008 |
| Inhalation of liposomal amphotericin B to prevent invasive aspergillosis |
Amphotericin B |
25 mg |
Phase II/III randomized double-blind study focused on the comparison of the safety and the efficacy of a weekly administration of 25 mg nebulised AmBisome® with nebulised placebo solution to prevent invasive pulmonary aspergillosis in neutropenic hemato-oncologic patients |
Erasmus Medical Center/2005–2006 |
| A study to access safety and efficacy of nebulised tobramycin in patients with bronchiectasis |
Tobramycin |
80 mg |
Randomized phase IV study based on the evaluation of the efficacy, indications, adverse reactions and resistance of combined administration of nebulised tobramycin compared with systemic administration alone in patients with bronchiectasis in acute exacerbation of bronchiectasis |
Shandong University/2012 |
| The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis |
Hypertonic Saline |
|
Randomized phase III study focused on the evaluation of the efficacy of inhalation of nebulised hypertonic saline on lung function with no adverse effects on infection and inflammation in adults and children with cystic fibrosis |
Royal Prince Alfred Hospital, Sydney, Australia/2005–2006 |
| Evaluation of a therapeutic strategy including nebulised liposomal amphotericin B (Ambisome®) in maintenance treatment of allergic bronchopulmonary aspergillosis (ABPA) |
Amphotericin B |
|
Phase II study based on the comparison of the incidence of severe clinical exacerbations in the treatment of ABPA, between a strategy with a maintenance treatment and a conventional strategy without antifungal maintenance therapy |
Poitiers University Hospital/2014–2017 |
| Nebulised amphotericin B lipid complex in invasive pulmonary aspergillosis (IPA) in paediatric patients with acute leukaemia |
Amphotericin B |
0.5 mg/kg three times weekly |
Phase II interventional study focused on the evaluation of the overall tolerability of the amphotericin B and the efficacy of aerolised amphotericin B as a lipid complex (ABLC) for primary prophylaxis of IPA in pediatric patients with acute leukemia undergoing intensive chemotherapy |
Fundació Sant Joan de Déu/2012–2015 |
| Ease of use and microbial contamination of tobramycin inhalation powder (TIP) versus nebulised tobramycin inhalation solution (TIS) and nebulised colistimethate (COLI) |
Tobramycin |
|
Phase IV interventional study focused on the evaluation of the ease of use of TIP and prevalence of microbial contamination of the T-326 Inhaler compared with TIS and colistimethate administered via nebuliser for the treatment of cystic fibrosis patients chronically infected with P. aeruginosa |
Novartis Pharmaceuticals/2013–2016 |
